Latest Partnerships News

Provaris Energy’s 2025 AGM highlights strategic progress in hydrogen and CO2 storage technologies, focusing on European market expansion and a refined licensing business model.

Tower Limited has reported a record underlying profit for FY25, driven by improved claims ratios, customer growth, and strategic initiatives including expanded risk-based pricing. The insurer declared increased dividends and outlined a positive growth outlook for FY26.

Redivium Limited has postponed the completion of its UK lithium-ion battery recycling feasibility study to Q2 2026 due to a site relocation requiring updated environmental assessments. Meanwhile, its European projects in Czechia and Romania continue to advance steadily.

Prophecy International Holdings and Complexica have mutually terminated their planned all-scrip merger, prompting Prophecy to cancel its intended $1.5 million on-market share buy-back.

Airtasker Limited showcased strong FY25 financials and unveiled aggressive growth plans in the UK and US, supported by strategic media partnerships and core platform investments.

Finder Energy’s Kuda Tasi and Jahal oil development project in Timor-Leste received strong government endorsement and an independent resource upgrade, accelerating its path to first oil by 2027.

Element 25 Limited has announced significant progress in expanding its Butcherbird manganese mine and developing a US-based high-purity manganese refinery, backed by substantial government grants and strategic partnerships with automotive giants.

MotorCycle Holdings Limited reported a robust 2025 financial year with record revenue and profit growth, strengthened by key acquisitions that expanded its market share to 22%. The company’s focus on operational efficiency and digital transformation sets the stage for continued momentum in 2026.

Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.